Literature DB >> 10872471

The 26S proteasome: a molecular machine designed for controlled proteolysis.

D Voges1, P Zwickl, W Baumeister.   

Abstract

In eukaryotic cells, most proteins in the cytosol and nucleus are degraded via the ubiquitin-proteasome pathway. The 26S proteasome is a 2.5-MDa molecular machine built from approximately 31 different subunits, which catalyzes protein degradation. It contains a barrel-shaped proteolytic core complex (the 20S proteasome), capped at one or both ends by 19S regulatory complexes, which recognize ubiquitinated proteins. The regulatory complexes are also implicated in unfolding and translocation of ubiquitinated targets into the interior of the 20S complex, where they are degraded to oligopeptides. Structure, assembly and enzymatic mechanism of the 20S complex have been elucidated, but the functional organization of the 19S complex is less well understood. Most subunits of the 19S complex have been identified, however, specific functions have been assigned to only a few. A low-resolution structure of the 26S proteasome has been obtained by electron microscopy, but the precise arrangement of subunits in the 19S complex is unclear.

Mesh:

Substances:

Year:  1999        PMID: 10872471     DOI: 10.1146/annurev.biochem.68.1.1015

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN: 0066-4154            Impact factor:   23.643


  513 in total

Review 1.  The proteasome: a macromolecular assembly designed for controlled proteolysis.

Authors:  P Zwickl; D Voges; W Baumeister
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-09-29       Impact factor: 6.237

2.  SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase.

Authors:  A Orian; H Gonen; B Bercovich; I Fajerman; E Eytan; A Israël; F Mercurio; K Iwai; A L Schwartz; A Ciechanover
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

4.  Covalent modifier NEDD8 is essential for SCF ubiquitin-ligase in fission yeast.

Authors:  F Osaka; M Saeki; S Katayama; N Aida; A Toh-E; K Kominami; T Toda; T Suzuki; T Chiba; K Tanaka; S Kato
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

5.  Developmentally regulated, alternative splicing of the Rpn10 gene generates multiple forms of 26S proteasomes.

Authors:  H Kawahara; M Kasahara; A Nishiyama; K Ohsumi; T Goto; T Kishimoto; Y Saeki; H Yokosawa; N Shimbara; S Murata; T Chiba; K Suzuki; K Tanaka
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

6.  A protein-protein interaction map of the Caenorhabditis elegans 26S proteasome.

Authors:  A Davy; P Bello; N Thierry-Mieg; P Vaglio; J Hitti; L Doucette-Stamm; D Thierry-Mieg; J Reboul; S Boulton; A J Walhout; O Coux; M Vidal
Journal:  EMBO Rep       Date:  2001-09       Impact factor: 8.807

7.  Overlapping recognition determinants within the ssrA degradation tag allow modulation of proteolysis.

Authors:  J M Flynn; I Levchenko; M Seidel; S H Wickner; R T Sauer; T A Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

8.  CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein.

Authors:  S Murata; Y Minami; M Minami; T Chiba; K Tanaka
Journal:  EMBO Rep       Date:  2001-11-21       Impact factor: 8.807

9.  Subunit interaction maps for the regulatory particle of the 26S proteasome and the COP9 signalosome.

Authors:  H Fu; N Reis; Y Lee; M H Glickman; R D Vierstra
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

10.  NEDD8 recruits E2-ubiquitin to SCF E3 ligase.

Authors:  T Kawakami; T Chiba; T Suzuki; K Iwai; K Yamanaka; N Minato; H Suzuki; N Shimbara; Y Hidaka; F Osaka; M Omata; K Tanaka
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.